Dr. Khanna began developing AAV-based gene therapies while at the University of Massachusetts Chan Medical School and was recruited to Iveric Bio to develop its preclinical research pipeline. Following the company’s acquisition by Astellas Pharma Inc., Dr. Khanna continues to lead investigational new drug (IND) enabling studies at Astellas and participates in regulatory discussions for AAV gene therapies like the one we aspire to develop. He has more than 20 years of experience in biomedical sciences, translational medicine, and drug discovery and development.